The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
The deal covers Interpace's ThyGenX and ThyraMir tests for thyroid cancer, as well as its PancraGen pancreatic cancer test.
In December, the company effected a 1-for-10 reverse stock split in order to help regain compliance with Nasdaq's minimum closing bid requirement.
The company said it will use the proceeds for working capital, repayment of indebtedness, and general corporate purposes.
Certain investors have agreed to buy 375,000 shares of Interpaces common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share.
Interpace hopes to keep its stock listed on the Nasdaq as a result of the reverse split.
A single institutional investor will purchase 2 million shares of Interpace's common stock and 1.6 million prefunded warrants to purchase its common stock.
The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.
The company said in a filing with the US Securities and Exchange Commission that it is not in compliance with the exchange's minimum shareholders' equity requirement.
Contributing to the revenue increase was a rise in in test and collection volume for its thyroid cancer diagnostics.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.